Dr. Michael Richard Hilleary, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 157 Holland Ave, Westover, WV 26501 Phone: 304-296-1721 Fax: 304-296-1115 |
Dr. Diana Oliver Frum, DDS Dentist Medicare: Medicare Enrolled Practice Location: 406 Holland Ave, Westover, WV 26501 Phone: 304-296-3786 Fax: 304-292-5925 |
Dr. Caroline G Labritz, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 406 Holland Avenue, Westover, WV 26501 Phone: 304-296-3786 Fax: 304-292-5925 |
Dr. Christopher J Giuliani, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 4 West Park, Westover, WV 26501 Phone: 304-296-6534 Fax: 304-292-4915 |
Emily Pettit Black, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 157 Holland Ave, Westover, WV 26501 Phone: 304-296-1721 |
Dr. Daniel Robert Taylor, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 157 Holland Ave, Westover, WV 26501 Phone: 304-296-1721 Fax: 304-296-1115 |
News Archive
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today it has initiated its ATHENA natural history of disease study in patients with Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
Risk of whooping cough (pertussis) is highest in infants too young to have completed their primary immunization series (6 months old or younger) and they are at highest risk of developing life-threatening complications.
Precyse, a leader in health information management (HIM) technologies and services, leading up to the 2012 American Health Information Management Association (AHIMA) Convention and Exhibit, released a new report titled, "Breaking the Code: The Impact of ICD-10 on Documentation and CDI Drives the Need for Organization-Wide Education."
Two easily measurable signs of health -; respiration rate and blood-oxygen saturation -; are distinctly predictive of higher mortality among patients hospitalized with COVID-19, according to a study examining the cases of inpatients with COVID-19 at Rush University Medical Center and University of Washington Medicine hospitals.
Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel's Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel's Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).
› Verified 6 days ago